Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK [Yahoo! Finance]
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Yahoo! Finance
Corcept Therapeutics rallied for a second day on Wednesday, soaring 19.66 percent to finish at $40.47 apiece, as investors snapped up shares after securing the green light of the Food and Drug Administration (FDA) to sell its ovarian cancer treatment, Lifyorli. In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that the approval was based on the success of its clinical trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy, including Bevacizumab. Photo by Gustavo Fring on Pexels During the study, the company found that patients treated with Lifyorli in combination with nab-paclitaxel experienced a 35 percent and 30 percent reduction in death risk and disease progression, respectively, as compared with those patients who took nab-paclitaxel alone. Lifyorli was also well-tolerated, having only recorded decreased hemoglobin and neutrophils, as well as fatigue, nausea, diarrhea, decreased plat
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORTGlobeNewswire
- Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant) [Yahoo! Finance]Yahoo! Finance
- CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent LossPR Newswire
- Deadline Alert: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud LawsuitGlobeNewswire
- Corcept Therapeutics (CORT) had its price target raised by Canaccord Genuity Group Inc. from $100.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
CORT
Earnings
- 2/24/26 - Miss
CORT
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/25/26 - Form 144
- 3/25/26 - Form 8-K
- CORT's page on the SEC website